LTS LOHMANN Therapie-Systeme AG (LTS), a leading pharmaceutical technology company, and Nualtis (formerly IntelGenx Corp.), an innovator in oral thin film (OTF) drug delivery technology, announced a strategic collaboration to provide customers with robust, reliable, high-quality and cost-competitive large-scale manufacturing capacities. The collaboration leverages LTS's global expertise in technology transfer, scale-up, and manufacturing, providing Nualtis with resources to scale their innovative OTF products and deliver them to patients worldwide.
Strategic Partnership Enhances Manufacturing Capabilities
The collaboration addresses the growing demand for advanced oral thin film technologies by combining complementary strengths. Nualtis has consistently demonstrated success in advancing OTF technologies, and as the company expands its pipeline of OTF programs, the partnership supports scalable growth while offering pharmaceutical partners greater supply chain flexibility and security.
"Teaming up Nualtis' excellent OTF Formulation platform with LTS's world-class manufacturing capabilities, allows the two companies to accelerate our shared vision of bringing patient-centric therapeutical solutions to our pharma partners," said Bas van Buijtenen, CEO of LTS. "It provides LTS with an exciting opportunity to extend the reach of our mission of 'We CARE, We CREATE, We DELIVER' to a wider range of molecules and therapies."
Expanding Market Position and Growth Capabilities
The strategic alliance positions both companies to strengthen their market leadership in oral thin film technology. For Nualtis, the collaboration provides access to LTS's extensive manufacturing infrastructure, complementing the company's in-house capabilities and ensuring support from early development through full-scale commercialization.
"Nualtis is entering a new phase of growth, and this collaboration ensures we are ready," said Dr. Michael Raven, CEO of Nualtis. "Working with LTS allows us to complement our in-house manufacturing capabilities - giving our partners the confidence that we can support them from early development through to full-scale commercialization."
Technology Platform Integration
LTS operates as a global leader in the development and manufacturing of oral thin films, maintaining more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. The company's commercial offering includes transdermal patches, oral thin films, and wearable drug delivery devices, with operations spanning four sites in Germany, the United States, and Israel.
Nualtis brings its superior film technologies, including VersaFilm®, DisinteQ™, VetaFilm®, and transdermal VevaDerm™, which enable next-generation pharmaceutical products that address unmet medical needs. The company's fully integrated platform encompasses research and development, analytical services, regulatory support, and scalable manufacturing from laboratory to market.
Advancing Patient-Centric Solutions
The collaboration aims to deliver advanced OTF therapies that improve patient outcomes and address pressing healthcare challenges. Both companies remain aligned in their commitment to delivering high-quality, reliable, and scalable OTF solutions that improve treatment outcomes across a broad range of therapeutic indications.
The partnership represents a significant step forward in expanding access to innovative drug delivery technologies, combining Nualtis' formulation expertise with LTS's proven manufacturing capabilities to support pharmaceutical partners throughout the drug development and commercialization process.
